Effect of Adalimumab on Work Productivity and Indirect Costs in Moderate to Severe Crohn’s Disease: A Meta-Analysis
| Autor: | Edouard Louis, Jingdong Chao, David G. Binion, Bas Oldenburg, Mei Yang, Arielle G. Bensimon, Parvez Mulani |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
musculoskeletal diseases
Moderate to severe Work medicine.medical_specialty Anti-Inflammatory Agents Efficiency Disease Antibodies Monoclonal Humanized Indirect costs Cost of Illness Crohn Disease Internal medicine Absenteeism Adalimumab medicine Humans lcsh:RC799-869 skin and connective tissue diseases Clinical Trials as Topic Crohn's disease Work productivity business.industry Gastroenterology General Medicine medicine.disease Clinical trial Meta-analysis Physical therapy lcsh:Diseases of the digestive system. Gastroenterology Original Article business medicine.drug |
| Zdroj: | Canadian Journal of Gastroenterology, Vol 25, Iss 9, Pp 492-496 (2011) |
| ISSN: | 0835-7900 |
| Popis: | OBJECTIVE: To assess the effect of adalimumab on work productivity and indirect costs in patients with Crohn’s disease (CD) using a meta-analysis of clinical trials.METHODS: Study-level results were pooled from all clinical trials of adalimumab for moderate to severe CD in which work productivity outcomes were evaluated. Work Productivity and Activity Impairment Questionnaire outcomes (absenteeism, presenteeism and total work productivity impairment [TWPI]) were extracted from adalimumab trials. Meta-analyses were used to estimate pooled averages and 95% CIs of one-year accumulated reductions in work productivity impairment with adalimumab. Pooled averages were multiplied by the 2008 United States national average annual salary ($44,101) to estimate per-patient indirect cost savings during the year following adalimumab initiation.RESULTS: The four included trials (ACCESS, CARE, CHOICE and EXTEND) represented a total of 1202 employed adalimumab-treated patients at baseline. Each study followed patients for a minimum of 20 weeks. Pooled estimates (95% CIs) of one-year accumulated work productivity improvements were as follows: −9% (−10% to −7%) for absenteeism; −22% (−26% to −18%) for presenteeism; and −25% (−30% to −20%) for TWPI. Reductions in absenteeism and TWPI translated into per-patient indirect cost savings (95% CI) of $3,856 ($3,183 to $4,529) and $10,964 ($8,833 to $13,096), respectively.CONCLUSION: Adalimumab provided clinically meaningful improvements in work productivity among patients with moderate to severe CD, which may translate into substantial indirect cost savings from an employer’s perspective. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|